# Azura Ophthalmics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/azura-ophthalmics

- Industry: Healthcare Specialists
- Headquarters: Tel Aviv-Yafo, Israel
- Website: www.azuraophthalmics.com
- Total disclosed funding: $30M
- Latest round: Series C (Oct 22, 2020)
- Investors on record: 5

## About

Azura Ophthalmics Ltd. is an innovative biotechnology company focused on developing therapies for ocular surface diseases through a new class of treatments known as Ophthalmic Keratolytics.Founded in 2014, Azura Ophthalmics Ltd. is based in Tel Aviv-Yafo, Israel, and is dedicated to addressing ocular surface diseases. The company has undergone three funding rounds, with the latest being a Series C round raising AUD 20.00 mn on September 7, 2022, with investors including Ganot, Medical Research Commercialisation Fund, OrbiMed Advisors, and TPG Biotech. The CEO, Marc Gleeson, leads the company as it aims to expand its reach in the ophthalmic market.Azura Ophthalmics specializes in developing a new class of therapies known as Ophthalmic Keratolytics, targeting ocular surface diseases. Their core product offerings focus on treating lid margin and ocular surface conditions by addressing the underlying pathophysiology, ultimately aiming to alleviate the signs and symptoms associated with these diseases. These innovative treatments are designed to revolutionize the management of ophthalmic conditions, particularly for patients who currently have limited options. Azura Ophthalmics actively engages with healthcare providers, ophthalmologists, and patients as part of their client base, ensuring that these advanced therapies reach those in need. While the company is positioned to enter various global markets, specific geographical expansions are strategically planned to enhance accessibility to their products.The financial model of Azura Ophthalmics is structured around direct sales of their Ophthalmic Keratolytics to healthcare providers and institutions specializing in eye care. The company engages in B2B transactions, establishing partnerships with medical distributors and wholesalers to facilitate the distribution of their products. These transactions involve pricing structures based on bulk purchases and contractual agreements with healthcare facilities, ensuring a steady supply of their therapeutic offerings. The flagship products, integral to Azura’s portfolio, are expected to contribute significantly to the company's revenue stream as they gain market traction. This sales approach positions the company to effectively meet the needs of their clientele while fostering long-term relationships within the ophthalmic healthcare sector.Azura Ophthalmics is advancing its growth strategy by focusing on the development of new products, particularly a two-stage study on AZR-MD-001, which will be supported by recent funding. The AUD 20.00 mn raised during the Series C round in September 2022 will facilitate these initiatives. Additionally, the company plans to explore specific global market expansions, with targeted geographical regions to increase the accessibility of their innovative therapies. The strategic use of funding is aimed at enhancing product development and market penetration.

## Funding rounds

- Series C, Oct 22, 2020, $14M — OrbiMed Advisors, TPG Biotech, Ganot, Medical Research Commercialisation Fund
- Series B, Oct 10, 2017, $16M — OrbiMed Advisors, Brandon Capital Partners, TPG Biotech, Ganot

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B, Series C
- Ganot (https://capitalatlas.ai/funds/ganot) — Series B, Series C
- Medical Research Commercialisation Fund — Series C